Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

NCT01255137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

NIH

Sponsor class

Conditions

Adrenal Cortex Neoplasms

Interventions

DRUG: Axitinib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]